Advancing Long-Term Arthritis Care at ACR 2020 - Episode 4
Elaine Husni, MD, MPH: I think your question about emerging therapies is really important right now, because we have so many to choose from, and this was not always the case. For patients with psoriatic arthritis, we've always had to borrow from rheumatoid arthritis. Basically, they would be studied in rheumatoid arthritis first, and then we would borrow what we've learned into psoriatic arthritis. And that has really been different now. At ACR 2020, we're really looking at all the different psoriatic arthritis treatments that have been designed and tested for psoriatic arthritis patients only, and that's really exciting.
That's because we understand more about the psoriatic arthritis disease processes now. We understand more about the pathophysiology of disease. We are also much, much more engaged in the different manifestations. It has a wide spectrum of clinical manifestations—not only the skin and the joints that are affected, but also the enthesitis, which is where the tendon meets the bone, and dactylitis, the swelling of the whole digit. In addition, there's also all these comorbidities that we're learning that are associated and related to psoriatic arthritis specifically, where we're trying to get more personalized in our treatment.